RC references
    Background
  1. Graves N, et al. Cost Data for Individual Patients Included in Clinical Studies: No Amount of Statistical Analysis Can Compensate for Inadequate Costing Methods. Health economics 2002; 11(8): 735-39.
  2. Halliday RG, Darba J. Cost Data Assessment in Multinational Economic Evaluations: Some Theory and Review of Published Studies. Applied health economics and health policy 2003; 2(3): 149-55.
  3. Hughes DA, Tilson L, Drummond M. Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations. PharmacoEconomics 2009; 27(8): 635-43.
  4. Frappier J, Tremblay G, Charny M, Cloutier LM. Costing bias in economic evaluations. J Med Econ 2015; 18(8): 596-9.
  5. Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. Health economics 2009; 18(4): 377-88.
  6. Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Medical care 2009; 47(7 Suppl 1): S28-32.
  7. Adam T, Evans DB, Koopmanschap MA. Cost-Effectiveness Analysis: Can We Reduce Variability in Costing Methods? International journal of technology assessment in health care 2003; 19(2): 407-20.
  8. AJ OC, Hanly P, Skally M, et al. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer. Medical care 2013; 51(4): 339-50.
  9. Fukuda H, Imanaka Y. Assessment of transparency of cost estimates in economic evaluations of patient safety programs. J Eval Clin Pract 2009; 15(3): 451-9.
  10. Kolaczinski J, Hanson K. Costing the distribution of insecticide-treated nets: a review of cost and cost-effectiveness studies to provide guidance on standardization of costing methodology. Malaria journal 2006; 5(37): 37.
  11. Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical review of the literature. Stroke; a journal of cerebral circulation 2009; 40(2): e18-23.
  12. Alvin MD, Miller JA, Lubelski D, et al. Variations in cost calculations in spine surgery cost-effectiveness research. Neurosurg Focus 2014; 36(6): E1.
  13. Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value Health 2016; 19(8): 921-8.
  14. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 2016; 316(10): 1093-103.
    15. Guide through the Reference Case
  15. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med 2010; 7(2): e1000217.
  16. Beck EJ, Beecham J, Mandalia S, et al. What is the cost of getting the price wrong? J Public Health Med 1999; 21(3): 311-7.
    17. Estimating the Cost of Health Interventions
  17. Wang H, Aas E, Roman E, Smith A. Comparison of different costing methods. Value in Health 2015; 18 (7): A687.
  18. Monge P. The importance of activity-based methods in radiology and the technology that now makes this possible. Radiol Manage 2006; 28(3): 52-5.
  19. Mercier G, Naro G. Costing hospital surgery services: the method matters. PLoS One 2014; 9(5): e97290.
    20. Reference Case approach
  20. Pooneh ST, C. Sadeghi, M. Variance reduction of Monte Carlo simulation in nuclear engineering field. . INTECH Open Access Publisher 2013.
  21. Wilson EC, Mugford M, Barton G, Shepstone L. Efficient Research Design: Using Value-of-Information Analysis to Estimate the Optimal Mix of Top-down and Bottom-up Costing Approaches in an Economic Evaluation alongside a Clinical Trial. Medical decision making : an international journal of the Society for Medical Decision Making 2016; 36(3).
    22. Study Design: Principles 1-5
  22. Gerves C, Chauvin P, Bellanger MM. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care. Health Policy 2014; 116(1): 114-22.
  23. Etzioni RD, et al. On the Use of Survival Analysis Techniques to Estimate Medical Care Costs. Journal of health economics 1999; 18(3): 365-80.
  24. Wang H, Aas E, Roman E, Smith A. Method comparison of censoring cost analyses. Value in Health 2015; 18 (7): A687.
  25. Edbrooke DL, Stevens VG, Hibbert CL, Mann AJ, Wilson AJ. A new method of accurately identifying costs of individual patients in intensive care: the initial results. Intensive Care Med 1997; 23(6): 645-50.
    26. Resource use measurement: Principles 6-10
  26. Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care 2009; 47(7 Suppl 1): S82-8.
  27. Cooper NJ MM, Symmons D. Development of resource-use and expenditure questionnaires for use in rheumatology research. The Journal of Rheumatology 2003; (30): 2485-91.
  28. Marseille E, Giganti MJ, Mwango A, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS One 2012; 7(12): e51993.
  29. Olchanski N, Zhong Y, Cohen JT, Saret C, Bala M, Neumann PJ. The peculiar economics of life-extending therapies: A review of costing methods in health economic evaluations in oncology. Expert Review of Pharmacoeconomics and Outcomes Research 2015; 15(6): 931-40.
  30. Gupta PK, Parmar NK. COSTING A HOSPITAL SERVICE PRODUCT: MARGINAL Vs ABSORPTION COSTING. Medical journal, Armed Forces India; 57(3).
  31. Tunceli O, Wade R, Gu T, Bouchard JR, Jennings NM, Luo W. Underestimating the true cost of diabetes: A matched case control versus disease attributable cost-of-illness analysis. Journal of Managed Care Pharmacy 2009; 15 (7): 602.
  32. Simpson AN, Bonilha HS, Kazley AS, Zoller JS, Ellis C. How big is the difference between marginal cost versus total cost estimates? The case of ischemic stroke in South Carolina (SC). Value in Health 2013; 16 (3): A281.
  33. Dakin H, Abangma G, Wordsworth S. What is the value of collecting detailed costing data in clinical trials? Trials 2011; 12(Suppl 1).
  34. Chapko MK, Liu CF, Perkins M, Li YF, Fortney JC, Maciejewski ML. Equivalence of two healthcare costing methods: bottom-up and top-down. Health economics 2009; 18(10): 1188-201.
  35. Cunnama L, Sinanovic E, Ramma L, et al. Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. Health Econ 2016; 25 Suppl 1: 53-66.
  36. Olsson TM. Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare. European Journal of Health Economics 2011; 12(5): 445-53.
  37. Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Roijen H-vL. Comparing methodologies for the cost estimation of hospital services. The European journal of health economics : HEPAC : health economics in prevention and care; 10(1).
  38. Javid M, Hadian M, Ghaderi H, Ghaffari S, Salehi M. Application of the Activity-Based Costing Method for Unit-Cost Calculation in a Hospital. Global journal of health science 2016; 8(1): 165-72.
  39. Conteh L. Cost and unit cost calculations using step-down accounting. Health policy and planning 2004; 19(2): 127-35.
  40. Federowicz MH, Grossman MN, Hayes BJ, Riggs J. A tutorial on activity-based costing of electronic health records. Quality management in health care 2010; 19(1).
  41. Kaplan RS, Anderson SR. Time-driven activity-based costing. Harv Bus Rev 2004; 82(11): 131-8, 50.
  42. Kaplan RS, Witkowski M, Abbott M, et al. Using time-driven activity-based costing to identify value improvement opportunities in healthcare. Journal of healthcare management / American College of Healthcare Executives 2014; 59(6): 399-412.
  43. Fukuda H, Lee J, Imanaka Y. Variations in analytical methodology for estimating costs of hospital-acquired infections: a systematic review. J Hosp Infect 2011; 77(2): 93-105.
  44. Gyllensten H, Jonsson AK, Rehnberg C, Carlsten A. How are the costs of drug-related morbidity measured?: a systematic literature review. Drug Saf 2012; 35(3): 207-19.
  45. Evans C, Crawford B, Doyle J. Usefulness of resource utilization estimates from piggyback studies in rheumatoid arthritis. Expert review of pharmacoeconomics & outcomes research 2003; 3(6): 685-9.
  46. O'Sullivan A K TD, Drummond M F. Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations? Value in Health 2005; (8): 67-79.
  47. Jacobs P, Ohinmaa A, Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. PharmacoEconomics 2005; 23(2): 143-53.
  48. Burnett L, Wilson R, Pfeffer S, Lowry J, BiPac. Benchmarking in pathology: development of an activity-based costing model. Pathology 2012; 44(7): 644-53.
  49. Hendriks ME, Kundu P, Boers AC, et al. Step-by-step guideline for disease-specific costing studies in low- and middle-income countries: a mixed methodology. Global health action 2014; 7: 23573.
  50. Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ 2009; 10(1): 39-45.
  51. Akhavan S, Ward L, Bozic KJ. Time-driven Activity-based Costing More Accurately Reflects Costs in Arthroplasty Surgery. Clin Orthop Relat Res 2016; 474(1): 8-15.
  52. Finkler SA, Knickman JR, Hendrickson G, Mack Lipkin J, Thompson WG. A Comparison of Work-Sampling and Time-and-Motion Techniques for Studies in Health Services Research. Health Services Research 1993; 28(5).
  53. Lopetegui M, Yen PY, Lai A, Jeffries J, Embi P, Payne P. Time motion studies in healthcare: what are we talking about? J Biomed Inform 2014; 49: 292-9.
  54. Bratt JH, Foreit J, Chen P-L, West C, Janowitz B, De Vargas T. A comparison of four approaches for measuring clinician time use. Health policy and planning 1999; 14(4): 374-81.
  55. Adam T, Evans DB, Murray CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003; 1(1): 3.
  56. Torgerson DJ, Campbell MK. Use of unequal randomisation to aid the economic efficiency of clinical trials. BMJ 2000; 321(7263): 759.
  57. Torgerson DJ, Campbell MK. Economics notes: cost effectiveness calculations and sample size. BMJ 2000; 321(7262): 697.
  58. Glick HA, et al. Design and Analysis of Unit Cost Estimation Studies: How Many Hospital Diagnoses? How Many Countries? Health economics 2003; 12(7): 517-27.
  59. Marques E JE, Gooberman-Hill R, Blom AW, Noble S. Using resource use logs to reduce the amount of missing data in economic evaluations alongside trials. Value in Health 2013; (16): 195-201.
  60. Heinrich S, Deister A, Birker T, et al. Accuracy of self-reports of mental health care utilization and calculated costs compared to hospital records. Psychiatry Res 2011; 185(1-2): 261-8.
  61. Byford S LM, Knapp M, et al. Comparison of alternative methods of collection of service use data for the economic evaluation of health care interventions. Health economics 2007: 531-6.
  62. Chou SL, Lamoureux E, Keeffe J. Methods for measuring personal costs associated with vision impairment. Ophthalmic Epidemiol 2006; 13(6): 355-63.
  63. Gordon LG, Patrao T, Hawkes AL. Can colorectal cancer survivors recall their medications and doctor visits reliably? BMC health services research 2012; (12): 440.
  64. Glandon GL, Counte MA, Tancredi D. An analysis of physician utilization by elderly persons: systematic differences between self-report and archival information. Journal of Gerontology 1992; (47): S245-S52.
  65. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP. Self-report versus care provider registration of healthcare utilization: impact on cost and cost-utility. Int J Technol Assess Health Care 2009; 25(4): 588-95.
  66. van den Brink M vdHW, Stiggelbout A, et al. Cost measurement in economic evaluation of health care. Whom to ask? Medical care 2004; (42): 740-6.
  67. Booth BM, Kirchner JE, Fortney SM, Han X, Thrush CR, French MT. Measuring use of health services for at-risk drinkers: how brief can you get? Journal of Behavioral Health Services & Research 2006; (33): 254-64.
  68. Grupp H, Koenig HH, Konnopka A. Cost measurement of mental disorders in Germany. J Ment Health Policy Econ 2014; 17(1): 3-8.
  69. Ghatnekar O, Liwing J, Aschan J, Mellqvist UH, Persson S. Comparing chart review and modified delphi panel resource data collection methods: The cost of treatment for multiple myeloma in Sweden. Value in Health 2009; 12 (3): A35.
  70. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev 2006; 63(2): 217-35.
  71. Briggs A, et al. Missing . . . Presumed at Random: Cost-Analysis of Incomplete Data. Health economics 2003; 12(5).
  72. Evans C J CB. Data collection methods in prospective economic evaluations: how accurate are the results? Value in Health 2000; (3): 277-86.
  73. Lamoureux EL, Chou SL, Larizza MF, Keeffe JE. The reliability of data collection periods of personal costs associated with vision impairment. Ophthalmic Epidemiol 2006; 13(2): 121-6.
  74. Clarke PM, Fiebig DG, Gerdtham UG. Optimal recall length in survey design. J Health Econ 2008; 27(5): 1275-84.
  75. Mauldin PD, Guimaraes P, Albin RL, et al. Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy. Clinical Therapeutics 2008; (30): 1553-7.
  76. Petrou S, Murray L, Cooper P, Davidson LL. The accuracy of self-reported healthcare resource utilization in health economic studies. Int J Technol Assess Health Care 2002; 18(3): 705-10.
    77. Pricing and valuation: Principles 11-14
  77. Riewpaiboon A, Malaroje S, Kongsawatt S. Effect of costing methods on unit cost of hospital medical services. Tropical Medicine and International Health 2007; 12(4): 554-63.
  78. Creese A, Parker, D. Cost Analysis in Primary Health Care. A Training Manual for Program Managers. WHO Publications Center USA, 49 Sheridan Avenue, Albany, NY 12210 1994.
  79. Mansley EC, Carroll NV, Chen KS, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report‒Part III. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 2010; 13(1): 14-7.
  80. Mullins CD, Seal B, Seoane-Vazquez E, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report‒Part IV. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 2010; 13(1): 18-24.
  81. Evans C, Mertzanis P, Abetz L. Measurement strategies for indirect costs in economic evaluations. Expert Rev Pharmacoecon Outcomes Res 2003; 3(6): 703-16.
  82. Hanly P, Ceilleachair AO, Skally M, et al. Time costs associated with informal care for colorectal cancer: an investigation of the impact of alternative valuation methods. Appl Health Econ Health Policy 2013; 11(3): 193-203.
    83. Analyzing and presenting results: Principles 15-17
  83. Dinan M, Morgan Dewitt E, Grussemeyer C, Reed SD. Comparison of inpatient cost estimation methods: Using data from a cystic fibrosis trial. Value in Health 2009; 12 (3): A7.
  84. Boulenger S, Nixon J, Drummond M, Ulmann P, Rice S, de Pouvourville G. Can Economic Evaluations Be Made More Transferable? European Journal of Health Economics 2005; 6(4): 334-46.
  85. Cartwright WS. A critical review of accounting and economic methods for estimating the costs of addiction treatment. J Subst Abuse Treat 2008; 34(3): 302-10.